Chitosan-coated PLGA nanoparticles as a delivery system for infectious bursal disease viral antigen in chickens.

IF 2.2 2区农林科学 Q1 VETERINARY SCIENCES

Avian Pathology Pub Date : 2025-09-12 DOI:10.1080/03079457.2025.2547584

Vimal Kumar, Sivasankar Panickan, Ananda Kumar, Saravanan Ramakrishnan, Sonal Saxena, Sameer Shrivastava, Satyabrata Dandapat

{"title":"Chitosan-coated PLGA nanoparticles as a delivery system for infectious bursal disease viral antigen in chickens.","authors":"Vimal Kumar, Sivasankar Panickan, Ananda Kumar, Saravanan Ramakrishnan, Sonal Saxena, Sameer Shrivastava, Satyabrata Dandapat","doi":"10.1080/03079457.2025.2547584","DOIUrl":null,"url":null,"abstract":"In the present study, antigen-chitosan-PLGA nanoparticles were explored as the delivery system for inactivated whole infectious bursal disease virus (IBDV) antigens. The immunized birds showed the peak antibody level (ELISA titre 4095.65 ± 55.74) at the 3rd week post-immunization, which was significantly higher than that of the commercial inactivated vaccine (titre 2257 ± 30) (P < 0.0001). The virus-loaded chitosan-coated PLGA nanoparticles induced good cell-mediated immunity. The immunized birds showed better resistance against the challenge infection with a very virulent IBDV. Only one bird out of the five challenged showed viral antigens in the bursa (80% protection), whereas, in the commercial vaccinated group, two chickens showed viral antigens in the bursa (60% protection). The histopathological lesions were also found to be very mild in the same group. The birds which were immunized with the antigen-chitosan-PLGA nanoparticles did not show any sign of immunosuppression. It is concluded that antigen-chitosan-PLGA nanoparticles afford the best protection among the groups, which lays a foundation for further development of a vaccine delivery platform in this line.RESEARCH HIGHLIGHTS First report on the use of Chitosan/PLGA nanoparticles with inactivated IBD virus.Nanoparticles prepared by solvent evaporation method.Elicited better humoral and cell-mediated immunity in chickens.Protection is better than commercial vaccine.","PeriodicalId":8788,"journal":{"name":"Avian Pathology","volume":" ","pages":"1-14"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avian Pathology","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1080/03079457.2025.2547584","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

In the present study, antigen-chitosan-PLGA nanoparticles were explored as the delivery system for inactivated whole infectious bursal disease virus (IBDV) antigens. The immunized birds showed the peak antibody level (ELISA titre 4095.65 ± 55.74) at the 3rd week post-immunization, which was significantly higher than that of the commercial inactivated vaccine (titre 2257 ± 30) (P < 0.0001). The virus-loaded chitosan-coated PLGA nanoparticles induced good cell-mediated immunity. The immunized birds showed better resistance against the challenge infection with a very virulent IBDV. Only one bird out of the five challenged showed viral antigens in the bursa (80% protection), whereas, in the commercial vaccinated group, two chickens showed viral antigens in the bursa (60% protection). The histopathological lesions were also found to be very mild in the same group. The birds which were immunized with the antigen-chitosan-PLGA nanoparticles did not show any sign of immunosuppression. It is concluded that antigen-chitosan-PLGA nanoparticles afford the best protection among the groups, which lays a foundation for further development of a vaccine delivery platform in this line.RESEARCH HIGHLIGHTS First report on the use of Chitosan/PLGA nanoparticles with inactivated IBD virus.Nanoparticles prepared by solvent evaporation method.Elicited better humoral and cell-mediated immunity in chickens.Protection is better than commercial vaccine.

查看原文本刊更多论文

壳聚糖包被PLGA纳米颗粒作为鸡传染性法氏囊病病毒抗原的递送系统。

在本研究中，抗原-壳聚糖- plga纳米颗粒已被探索作为整个IBD病毒抗原灭活的递送系统。免疫后第3周抗体水平达到峰值（ELISA滴度4095.65±55.74），显著高于市售灭活疫苗（滴度2257±30）(P

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Avian Pathology 农林科学-兽医学

CiteScore

4.50

自引率

10.70%

发文量

审稿时长

1 months

期刊介绍： Avian Pathology is the official journal of the World Veterinary Poultry Association and, since its first publication in 1972, has been a leading international journal for poultry disease scientists. It publishes material relevant to the entire field of infectious and non-infectious diseases of poultry and other birds. Accepted manuscripts will contribute novel data of interest to an international readership and will add significantly to knowledge and understanding of diseases, old or new. Subject areas include pathology, diagnosis, detection and characterisation of pathogens, infections of possible zoonotic importance, epidemiology, innate and immune responses, vaccines, gene sequences, genetics in relation to disease and physiological and biochemical changes in response to disease. First and subsequent reports of well-recognized diseases within a country are not acceptable unless they also include substantial new information about the disease or pathogen. Manuscripts on wild or pet birds should describe disease or pathogens in a significant number of birds, recognizing/suggesting serious potential impact on that species or that the disease or pathogen is of demonstrable relevance to poultry. Manuscripts on food-borne microorganisms acquired during or after processing, and those that catalogue the occurrence or properties of microorganisms, are unlikely to be considered for publication in the absence of data linking them to avian disease.